BTIG Research Boosts Establishment Labs (NASDAQ:ESTA) Price Target to $70.00

Establishment Labs (NASDAQ:ESTA) had its price objective increased by BTIG Research from $62.00 to $70.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s target price would indicate a potential upside of 14.74% from the stock’s previous close.

Several other research firms have also issued reports on ESTA. Citigroup reissued a “neutral” rating on shares of Establishment Labs in a report on Tuesday, October 7th. Wall Street Zen raised shares of Establishment Labs from a “sell” rating to a “hold” rating in a research note on Sunday, October 19th. Mizuho boosted their price objective on shares of Establishment Labs from $58.00 to $70.00 and gave the company an “outperform” rating in a research report on Wednesday, July 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Establishment Labs in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group started coverage on shares of Establishment Labs in a research report on Wednesday, August 20th. They issued a “buy” rating and a $60.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $57.83.

Establishment Labs Stock Up 23.5%

Shares of NASDAQ ESTA traded up $11.61 during midday trading on Wednesday, hitting $61.01. The stock had a trading volume of 1,252,233 shares, compared to its average volume of 482,887. The business’s 50 day moving average is $42.82 and its 200-day moving average is $39.84. The company has a market cap of $1.77 billion, a P/E ratio of -20.01 and a beta of 0.98. Establishment Labs has a 52 week low of $26.56 and a 52 week high of $61.18. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 9.71.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.16. Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.During the same period in the previous year, the firm posted ($0.59) EPS. Establishment Labs’s revenue was up 33.8% on a year-over-year basis. Establishment Labs has set its FY 2025 guidance at EPS. As a group, analysts predict that Establishment Labs will post -2.41 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC increased its holdings in Establishment Labs by 7.2% in the first quarter. Nantahala Capital Management LLC now owns 1,774,044 shares of the company’s stock valued at $72,390,000 after buying an additional 119,574 shares in the last quarter. Tyro Capital Management LLC increased its stake in shares of Establishment Labs by 0.3% in the 2nd quarter. Tyro Capital Management LLC now owns 1,066,721 shares of the company’s stock valued at $45,560,000 after purchasing an additional 2,835 shares in the last quarter. Bamco Inc. NY increased its stake in shares of Establishment Labs by 21.5% in the 2nd quarter. Bamco Inc. NY now owns 907,537 shares of the company’s stock valued at $38,761,000 after purchasing an additional 160,755 shares in the last quarter. William Blair Investment Management LLC increased its position in shares of Establishment Labs by 2.1% in the second quarter. William Blair Investment Management LLC now owns 865,244 shares of the company’s stock valued at $36,955,000 after buying an additional 17,855 shares in the last quarter. Finally, Rice Hall James & Associates LLC increased its position in shares of Establishment Labs by 7.4% in the first quarter. Rice Hall James & Associates LLC now owns 827,423 shares of the company’s stock valued at $33,763,000 after buying an additional 56,756 shares in the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.